{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:50:43Z","timestamp":1790913043900,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To assess the impact of mirabegron, a novel \u03b23 adrenoceptor agonist employed for the treatment of overactive bladder (OAB), on the optic nerve head and chorioretinal vasculature using optical coherence tomography angiography (OCTA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Fifty eyes of 25 patients who used a 50\u2009mg tablet of mirabegron once daily for OAB were included in this prospective study. OCTA was performed at 6\u2009\u00d7\u20096\u2009mm of the macula and 4.5\u2009\u00d7\u20094.5\u2009mm of the optic disc. Retinal nerve fiber layer (RNFL) thickness, macular ganglion cell complex(mGCC) thickness, foveal avascular zone (FAZ), choriocapillaris (CC) flow area, CC vessel flow density (VFD), optic nerve head, and macula vessel densities were evaluated before the treatment and 2 months after treatment initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      RNFL, mGCC in all quadrants, and FAZ were similar before and 2 months after treatment started point. In optic nerve head vessel density measurements, whole image vessel density (wiVD), mean ppVD (peripapillary vessel density), inferior ppVD, and ppVD in nasal superior, inferior nasal, and temporal superior quadrants measurements following mirabegron treatment were found to be lower than the pretreatment measurements (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Following treatment, wiVD decreased by 1.2% (Cohen's d\u2009=\u20090.26) and mean ppVD decreased by 0.8% (Cohen's d\u2009=\u20090.25), indicating a small effect size. All macular parameters were similar before and 2 months after treatment. No statistically differences were observed in terms of CC parameters.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The reduction in optic nerve head vascularity parameters following mirabegron treatment contributes to understanding the impact of \u03b23\u2010AR agonists, which are being investigated as a therapeutic target for treating retinal vascular diseases. These findings may provide valuable insight into the systemic vascular effects of \u03b23\u2010adrenergic agonists and could be relevant in shaping therapeutic strategies aimed at preserving optic nerve head perfusion, particularly in patients at risk of vascular compromise. Further studies with larger cohorts and longer follow\u2010up are needed to validate these preliminary findings.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Trial Registration:<\/jats:bold>\n                      This study is a prospective observational study and does not qualify as a clinical trial. Therefore, registration is not required.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/nau.70108","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T02:38:47Z","timestamp":1750905527000},"page":"1503-1511","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Analyzing the Impact of a New \u03b23 Adrenergic Agonist on Chorioretinal and Peripapillary Vessel Density"],"prefix":"10.1002","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0903-1818","authenticated-orcid":false,"given":"Meryem Feyza","family":"Cicek","sequence":"first","affiliation":[{"name":"Department of Ophthalmology University of Health Sciences, Haseki Training and Research Hospital Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7173-8617","authenticated-orcid":false,"given":"Abdullah","family":"A\u011f\u0131n","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology University of Health Sciences, Haseki Training and Research Hospital Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2791-5684","authenticated-orcid":false,"given":"Burcu","family":"Yakut","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology University of Health Sciences, Haseki Training and Research Hospital Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1993-0403","authenticated-orcid":false,"given":"Ata","family":"Baytaroglu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Hacettepe University School of Medicine Ankara Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8061-6950","authenticated-orcid":false,"given":"Mucahit","family":"Gelmis","sequence":"additional","affiliation":[{"name":"Department of Urology University of Health Sciences, Haseki Training and Research Hospital Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8712-7458","authenticated-orcid":false,"given":"Faruk","family":"Ozgor","sequence":"additional","affiliation":[{"name":"Department of Urology University of Health Sciences, Haseki Training and Research Hospital Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3752-9181","authenticated-orcid":false,"given":"Feyza","family":"Onder","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology University of Health Sciences, Haseki Training and Research Hospital Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"issue":"4","key":"e_1_2_10_2_1","first-page":"98","article-title":"Impact of Overactive Bladder on Work Productivity in the United States: Results From EpiLUTS","volume":"15","author":"Sexton C. C.","year":"2009","journal-title":"American Journal of Managed Care"},{"issue":"3","key":"e_1_2_10_3_1","first-page":"935","article-title":"Mirabegron for Overactive Bladder: A Novel, First\u2010in\u2010Class \u03b23\u2010Agonist Therapy","volume":"10","author":"Imran M.","year":"2013","journal-title":"Urology Journal"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2006.06679.x"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1159\/000055622"},{"issue":"7","key":"e_1_2_10_6_1","first-page":"2340","article-title":"Nitric Oxide and endothelin\u20101 Are Important Regulators of Human Ophthalmic Artery","volume":"33","author":"Haefliger I. O.","year":"1992","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"10","key":"e_1_2_10_7_1","first-page":"3279","article-title":"Rat Retinal Tissue Releases a Vasorelaxing Factor","volume":"43","author":"Boussery K.","year":"2002","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2006.09.002"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2008.06.001"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2007.05.052"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.91005.2008"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-010-0526-5"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-011-0682-2"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-013-0835-6"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-012-0828-x"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells11081271"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-5536"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-012-0796-1"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1364\/BOE.3.003127"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-8481"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.15-18932"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(86)90396-3"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M300368200"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.01273.2010"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.4149\/gpb_2011_01_90"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.1250"},{"issue":"11","key":"e_1_2_10_27_1","first-page":"3607","article-title":"Lipid Peroxidation and Peroxynitrite in Retinal Ischemia\u2010Reperfusion Injury","volume":"41","author":"Shibuki H.","year":"2000","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0039-6257(97)84043-x"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.149286"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106713"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.62.9.17"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.70108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T07:31:20Z","timestamp":1754292680000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.70108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1002\/nau.70108"],"URL":"https:\/\/doi.org\/10.1002\/nau.70108","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"assertion":[{"value":"2025-01-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}